PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2021-05-02
Target enrollment:
Participant gender:
Summary
This study is a single center, phase II study, to evaluate the effectiveness and safety of
PD-1 Antibody(SHR-1210) Plus apatinib Combined With POF(paclitaxel plus oxaliplatin plus
5-fluorouracil plus leucovorin) , in the first-line treatment for patients with
advanced/metastatic gastric cancer.